Efficacy and safety of carbon-ion radiotherapy for the malignant melanoma: A systematic review.
Chengcheng LiQiuning ZhangZheng LiShuangwu FengHongtao LuoRuifeng LiuLina WangYichao GengXueshan ZhaoZhen YangQiang LiKe-Hu YangXiaohu WangPublished in: Cancer medicine (2020)
Malignant melanomas (MMs) were the fifth most common cancer in men and the sixth most common cancer in women in 2018, respectively. These are characterized by high metastatic rates and poor prognoses. We systematically reviewed safety and efficacy of carbon-ion radiotherapy (CIRT) for treating MMs. Eleven studies were eligible for review, and the data showed that MM patients showed better local control with low recurrence and mild toxicities after CIRT. Survival rates were slightly higher in patients with cutaneous or uveal MMs than in those with mucosal MMs. CIRT in combination with chemotherapy produced higher progression-free survival rates than CIRT only. In younger patients, higher rates of distant metastases of gynecological MMs were observed. The data indicated that CIRT is effective and safe for treating MMs; however, a combination with systemic therapy is recommended to ensure the best possible prognosis for MMs.
Keyphrases
- free survival
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- early stage
- small cell lung cancer
- locally advanced
- papillary thyroid
- squamous cell carcinoma
- radiation therapy
- peritoneal dialysis
- electronic health record
- young adults
- stem cells
- skeletal muscle
- big data
- mesenchymal stem cells
- metabolic syndrome
- type diabetes
- adipose tissue
- radiation induced
- data analysis
- insulin resistance
- bone marrow
- lymph node metastasis